Aspen Pharmacare Holdings Stock Current Valuation
Valuation analysis of Aspen Pharmacare Holdings helps investors to measure Aspen Pharmacare's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Aspen Pharmacare Holdings Company Current Valuation Analysis
Aspen Pharmacare's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Aspen Pharmacare Current Valuation | 4.58 B |
Most of Aspen Pharmacare's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aspen Pharmacare Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Aspen Pharmacare Holdings has a Current Valuation of 4.58 B. This is 68.14% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 72.47% higher than that of the company.
Aspen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aspen Pharmacare's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aspen Pharmacare could also be used in its relative valuation, which is a method of valuing Aspen Pharmacare by comparing valuation metrics of similar companies.Aspen Pharmacare is currently under evaluation in current valuation category among its peers.
Aspen Fundamentals
| Return On Equity | 0.095 | |||
| Return On Asset | 0.0499 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 4.58 B | |||
| Shares Outstanding | 444.95 M | |||
| Shares Owned By Insiders | 19.32 % | |||
| Shares Owned By Institutions | 60.77 % | |||
| Price To Earning | 11.83 X | |||
| Price To Book | 0.98 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 38.61 B | |||
| Gross Profit | 18.29 B | |||
| EBITDA | 10.61 B | |||
| Net Income | 6.49 B | |||
| Cash And Equivalents | 7.88 B | |||
| Cash Per Share | 17.25 X | |||
| Total Debt | 105 M | |||
| Debt To Equity | 0.38 % | |||
| Current Ratio | 1.96 X | |||
| Book Value Per Share | 159.44 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 0.80 X | |||
| Number Of Employees | 8.58 K | |||
| Beta | 0.62 | |||
| Market Capitalization | 3.92 B | |||
| Total Asset | 111.38 B | |||
| Retained Earnings | 28.4 B | |||
| Working Capital | 16.1 B | |||
| Current Asset | 37.2 B | |||
| Current Liabilities | 21.1 B | |||
| Z Score | 22.2 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 111.38 B | |||
| Last Dividend Paid | 3.26 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Aspen Pink Sheet
If you are still planning to invest in Aspen Pharmacare Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aspen Pharmacare's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |